

François R Jornayvaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2119640/publications.pdf>

Version: 2024-02-01

74
papers

5,658
citations

109137

35
h-index

79541

73
g-index

103
all docs

103
docs citations

103
times ranked

10630
citing authors

#	ARTICLE	IF	CITATIONS
1	Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cells. <i>Molecular and Cellular Endocrinology</i> , 2022, 541, 111503.	1.6	9
2	NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. <i>Antioxidants</i> , 2022, 11, 1131.	2.2	20
3	Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity. <i>Endocrine Connections</i> , 2022, 11, .	0.8	2
4	Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesis. <i>Nature Communications</i> , 2022, 13, .	5.8	6
5	Three Weeks Versus Six Weeks of Antibiotic Therapy for Diabetic Foot Osteomyelitis: A Prospective, Randomized, Noninferiority Pilot Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e1539-e1545.	2.9	45
6	The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. <i>Translational Research</i> , 2021, 227, 75-88.	2.2	61
7	Is routine measurement of the serum <sc>C-reactive</sc> protein level helpful during antibiotic therapy for diabetic foot infection?. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 637-641.	2.2	10
8	Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients. <i>Acta Physiologica</i> , 2021, 232, e13610.	1.8	29
9	Pathophysiology of NASH in endocrine diseases. <i>Endocrine Connections</i> , 2021, 10, R52-R65.	0.8	43
10	Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12797.	1.8	28
11	Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 759-766.	2.2	10
12	Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report. <i>BMC Endocrine Disorders</i> , 2020, 20, 155.	0.9	13
13	<p>Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 2359-2365.	1.1	3
14	Thirteen-year trends in the prevalence of diabetes according to socioeconomic condition and cardiovascular risk factors in a Swiss population. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001273.	1.2	8
15	MON-235 Mycobacterium Fortuitum Infection Mimicking Sellar Chondrosarcoma in a Non-Immunosuppressed Patient: An Unusual Cause of Hypopituitarism and Oculomotor Nerve Palsy. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
16	Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism. <i>Scientific Reports</i> , 2019, 9, 16810.	1.6	34
17	Consequences of the Adoption of the IADPSG versus Carpenter and Coustan Criteria to Diagnose Gestational Diabetes: A Before-After Comparison. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 473-476.	0.6	3
18	Nonalcoholic fatty liver disease burden â€“ Switzerland 2018â€“2030. <i>Swiss Medical Weekly</i> , 2019, 149, w20152.	0.8	12

#	ARTICLE	IF	CITATIONS
19	Salivary cortisol is not associated with incident insulin resistance or type 2 diabetes mellitus. <i>Endocrine Connections</i> , 2019, 8, 870-877.	0.8	4
20	Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives. <i>Endocrine Reviews</i> , 2018, 39, 960-989.	8.9	67
21	An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb Ischemia. <i>Current Pharmaceutical Design</i> , 2018, 24, 1243-1254.	0.9	18
22	Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid. <i>Dermatology</i> , 2017, 233, 401-403.	0.9	30
23	AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient mice. <i>Molecular Metabolism</i> , 2017, 6, 1625-1633.	3.0	25
24	Grip strength is not associated with incident type 2 diabetes mellitus in healthy adults: The CoLaus study. <i>Diabetes Research and Clinical Practice</i> , 2017, 132, 144-148.	1.1	27
25	GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on bone. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1600219.	1.5	9
26	Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies. <i>Nutrients</i> , 2017, 9, 517.	1.7	146
27	Effects of Antidiabetic Drugs on Gut Microbiota Composition. <i>Genes</i> , 2017, 8, 250.	1.0	104
28	Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2017, 9, 1077.	1.7	12
29	Î ² -Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue. <i>JCI Insight</i> , 2017, 2, .	2.3	41
30	Treatment challenges in type 1 diabetes after roux-en-Y gastric bypass. <i>Swiss Medical Weekly</i> , 2017, 147, w14420.	0.8	0
31	Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study. <i>Cardiovascular Diabetology</i> , 2016, 15, 73.	2.7	190
32	Leptin as a Potential Regulator of FGF21. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 1218-1225.	1.1	32
33	Secondâ€generation antisense oligonucleotides against Î ² -catenin protect mice against dietâ€induced hepatic steatosis and hepatic and peripheral insulin resistance. <i>FASEB Journal</i> , 2016, 30, 1207-1217.	0.2	20
34	Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 817-824.	1.1	61
35	Preserving of Postnatal Leptin Signaling in Obesity-Resistant Lou/C Rats following a Perinatal High-Fat Diet. <i>PLoS ONE</i> , 2016, 11, e0162517.	1.1	4
36	Free Fatty Acids Impair FGF21 Action in HepG2 Cells. <i>Cellular Physiology and Biochemistry</i> , 2015, 37, 1767-1778.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?. <i>Molecular and Cellular Endocrinology</i> , 2015, 418, 55-65.	1.6	244
38	Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21. <i>Journal of Endocrinology</i> , 2015, 226, 207-217.	1.2	41
39	Serum Vitamin D Concentrations Are Not Associated with Insulin Resistance in Swiss Adults. <i>Journal of Nutrition</i> , 2015, 145, 2117-2122.	1.3	22
40	ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content. <i>Journal of Lipid Research</i> , 2015, 56, 526-536.	2.0	45
41	Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue. <i>PLoS ONE</i> , 2015, 10, e0126364.	1.1	50
42	Endocrine causes of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11053.	1.4	69
43	Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 Diabetes. <i>Journal of General Internal Medicine</i> , 2014, 29, 356-356.	1.3	0
44	Diets and nonalcoholic fatty liver disease: The good and the bad. <i>Clinical Nutrition</i> , 2014, 33, 186-190.	2.3	137
45	Muscle-specific activation of Ca ²⁺ /calmodulin-dependent protein kinase IV increases whole-body insulin action in mice. <i>Diabetologia</i> , 2014, 57, 1232-1241.	2.9	12
46	Ost α^{\pm} mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, G425-G438.	1.6	14
47	Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside. <i>Diabetes and Metabolism</i> , 2013, 39, 16-26.	1.4	93
48	Cellular Mechanism by Which Estradiol Protects Female Ovariectomized Mice From High-Fat Diet-Induced Hepatic and Muscle Insulin Resistance. <i>Endocrinology</i> , 2013, 154, 1021-1028.	1.4	154
49	Cellular Mechanisms by Which FGF21 Improves Insulin Sensitivity in Male Mice. <i>Endocrinology</i> , 2013, 154, 3099-3109.	1.4	184
50	Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. <i>Journal of Endocrinology</i> , 2013, 218, R25-R36.	1.2	243
51	Increased FGF21 plasma levels in humans with sepsis and SIRS. <i>Endocrine Connections</i> , 2013, 2, 146-153.	0.8	47
52	CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1869-1874.	3.3	137
53	Dissociation of Inositol-requiring Enzyme (IRE1)-mediated c-Jun N-terminal Kinase Activation from Hepatic Insulin Resistance in Conditional X-box-binding Protein-1 (XBP1) Knock-out Mice. <i>Journal of Biological Chemistry</i> , 2012, 287, 2558-2567.	1.6	132
54	Weight and Mortality in Adults With Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2080.	3.8	2

#	ARTICLE	IF	CITATIONS
55	Thyroid Hormone Receptor- β Gene Knockout Mice Are Protected from Diet-Induced Hepatic Insulin Resistance. <i>Endocrinology</i> , 2012, 153, 583-591.	1.4	66
56	Diacylglycerol Activation of Protein Kinase C δ and Hepatic Insulin Resistance. <i>Cell Metabolism</i> , 2012, 15, 574-584.	7.2	247
57	A Rare Cause of Hypertestosteronemia in a 68-Year-Old Patient: A Leydig Cell Tumor Due to a Somatic <i>GNAS</i> (<i>Guanine Nucleotide-Binding Protein, Alpha-Stimulating Activity Polypeptide</i>) Tj ETQq1 1 0.784204 rgbT f@verloc	1.0	4
58	Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients. <i>Acta Diabetologica</i> , 2012, 49, 161-169.	1.2	27
59	Development of insulin resistance in mice lacking PGC-1 β in adipose tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9635-9640.	3.3	248
60	Deletion of the Mammalian INDY Homolog Mimics Aspects of Dietary Restriction and Protects against Adiposity and Insulin Resistance in Mice. <i>Cell Metabolism</i> , 2011, 14, 184-195.	7.2	193
61	Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. <i>Hepatology</i> , 2011, 54, 1650-1660.	3.6	114
62	Pregnancy Does Not Accelerate Corticotroph Tumor Progression in Nelson's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E658-E662.	1.8	24
63	Diet, Lifestyle, and Long-Term Weight Gain. <i>New England Journal of Medicine</i> , 2011, 365, 1058-1059.	13.9	5
64	Fibroblast growth factor 21, ketogenic diets, and insulin resistance. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 955-961.	2.2	4
65	SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β -Cell Function. <i>Diabetes</i> , 2011, 60, 890-898.	0.3	197
66	Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5748-5752.	3.3	139
67	Influence of the Hepatic Eukaryotic Initiation Factor 2 β (eIF2 β) Endoplasmic Reticulum (ER) Stress Response Pathway on Insulin-mediated ER Stress and Hepatic and Peripheral Glucose Metabolism. <i>Journal of Biological Chemistry</i> , 2011, 286, 36163-36170.	1.6	65
68	A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E808-E815.	1.8	174
69	Regulation of mitochondrial biogenesis. <i>Essays in Biochemistry</i> , 2010, 47, 69-84.	2.1	789
70	Targeted Expression of Catalase to Mitochondria Prevents Age-Associated Reductions in Mitochondrial Function and Insulin Resistance. <i>Cell Metabolism</i> , 2010, 12, 668-674.	7.2	274
71	The Role of Muscle Insulin Resistance in the Pathogenesis of Atherogenic Dyslipidemia and Nonalcoholic Fatty Liver Disease Associated with the Metabolic Syndrome. <i>Annual Review of Nutrition</i> , 2010, 30, 273-290.	4.3	105
72	Assessment of Hepatic Glucose Metabolism by Indirect Calorimetry in Combination with a Non-Invasive Technique Using Naturally Enriched ¹³ C Glucose in Healthy Children and Adolescents. <i>Hormone Research in Paediatrics</i> , 2004, 62, 142-148.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Metabolism of oral glucose in children born small for gestational age: evidence for an impaired whole body glucose oxidation. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 847-851.	1.5	31
74	Agenesis of Human Pancreas due to Decreased Half-Life of Insulin Promoter Factor 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4398-4406.	1.8	158